Paroxetine-Overview of the Molecular Mechanisms of Action

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Feb 10

PMID 33562229

Citations 14

Authors

Magdalena Kowalska

Jacek Nowaczyk

Lukasz Fijalkowski

Alicja Nowaczyk

Affiliations

Soon will be listed here.

Abstract

In the 21st century and especially during a pandemic, the diagnosis and treatment of depression is an essential part of the daily practice of many family doctors. It mainly affects patients in the age category 15-44 years, regardless of gender. Anxiety disorders are often diagnosed in children and adolescents. Social phobias can account for up to 13% of these diagnoses. Social anxiety manifests itself in fear of negative social assessment and humiliation, which disrupts the quality of social functioning. Treatment of the above-mentioned disorders is based on psychotherapy and pharmacotherapy. Serious side effects or mortality from antidepressant drug overdose are currently rare. Recent studies indicate that paroxetine (ATC code: N06AB), belonging to the selective serotonin reuptake inhibitors, has promising therapeutic effects and is used off-label in children and adolescents. The purpose of this review is to describe the interaction of paroxetine with several molecular targets in various points of view including the basic chemical and pharmaceutical properties. The central point of the review is focused on the pharmacodynamic analysis based on the molecular mechanism of binding paroxetine to various therapeutic targets.

Citing Articles

Heterocyclic Antidepressants with Antimicrobial and Fungicide Activity.

Zolotareva D, Zazybin A, Belyankova Y, Bayazit S, Dauletbakov A, Seilkhanov T Molecules. 2025; 30(5).

PMID: 40076325 PMC: 11902072. DOI: 10.3390/molecules30051102.

Two-Step Constitutional Isomerization of Saturated Cyclic Amines Using Borane Catalysis.

Amber C, Petitjean T, Sirvinskaite G, Steele R, Sprague B, Domack J JACS Au. 2025; 5(2):851-857.

PMID: 40017774 PMC: 11862921. DOI: 10.1021/jacsau.4c01093.

Pharmacological Mechanism and Drug Research Prospects of Ginsenoside Rb1 as an Antidepressant.

Zhuang S, Shi F, Cannella N, Ubaldi M, Ciccocioppo R, Li H Antioxidants (Basel). 2025; 14(2).

PMID: 40002422 PMC: 11851604. DOI: 10.3390/antiox14020238.

GPCR Inhibitors Have Antiviral Properties against JC Polyomavirus Infection.

Sandberg A, Bond A, Bennett L, Craig S, Winski D, Kirkby L Viruses. 2024; 16(10).

PMID: 39459893 PMC: 11512265. DOI: 10.3390/v16101559.

Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths.

Aly S, Hennart B, Gaulier J, Allorge D Toxics. 2024; 12(4).

PMID: 38668482 PMC: 11054314. DOI: 10.3390/toxics12040260.

References

Lin J, Lu A . Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998; 35(5):361-90. DOI: 10.2165/00003088-199835050-00003. View

Li X, Hou Y, Su Y, Liu H, Zhang B, Fang S . Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020; 99(14):e19573. PMC: 7220791. DOI: 10.1097/MD.0000000000019573. View

Andersen J, Ringsted K, Bang-Andersen B, Stromgaard K, Kristensen A . Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter. Sci Rep. 2015; 5:15650. PMC: 4621520. DOI: 10.1038/srep15650. View

Patetsos E, Horjales-Araujo E . Treating Chronic Pain with SSRIs: What Do We Know?. Pain Res Manag. 2016; 2016:2020915. PMC: 4947493. DOI: 10.1155/2016/2020915. View

Cho Y, Kim E, Nyiramana M, Shin E, Jin H, Ryu J . Paroxetine Induces Apoptosis of Human Breast Cancer MCF-7 Cells through Ca-and p38 MAP Kinase-Dependent ROS Generation. Cancers (Basel). 2019; 11(1). PMC: 6356564. DOI: 10.3390/cancers11010064. View

Hao Z, Sadek I . Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016; 9:5495-505. PMC: 5021055. DOI: 10.2147/OTT.S112242. View

Rooney A, Grant R . Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database Syst Rev. 2010; (3):CD006932. DOI: 10.1002/14651858.CD006932.pub2. View

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

Knappe S, Beesdo-Baum K, Fehm L, Lieb R, Wittchen H . Characterizing the association between parenting and adolescent social phobia. J Anxiety Disord. 2012; 26(5):608-16. DOI: 10.1016/j.janxdis.2012.02.014. View

10.

Coleman J, Gouaux E . Structural basis for recognition of diverse antidepressants by the human serotonin transporter. Nat Struct Mol Biol. 2018; 25(2):170-175. PMC: 5962350. DOI: 10.1038/s41594-018-0026-8. View

11.

Thal D, Homan K, Chen J, Wu E, Hinkle P, Huang Z . Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol. 2012; 7(11):1830-9. PMC: 3500392. DOI: 10.1021/cb3003013. View

12.

Ren Y, Chen X, Feng M, Wang Q, Zhou P . Gaussian process: a promising approach for the modeling and prediction of Peptide binding affinity to MHC proteins. Protein Pept Lett. 2011; 18(7):670-8. DOI: 10.2174/092986611795445978. View

13.

Abramyan A, Slack R, Meena S, Davis B, Newman A, Singh S . Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics. Neuropharmacology. 2018; 161:107411. PMC: 6494725. DOI: 10.1016/j.neuropharm.2018.10.040. View

14.

Yamashita A, Singh S, Kawate T, Jin Y, Gouaux E . Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature. 2005; 437(7056):215-23. DOI: 10.1038/nature03978. View

15.

Davis B, Nagarajan A, Forrest L, Singh S . Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter. Sci Rep. 2016; 6:23789. PMC: 4817154. DOI: 10.1038/srep23789. View

16.

Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H . Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1999; 28(12):1203-53. DOI: 10.1080/004982598238886. View

17.

Zanger U, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. DOI: 10.1016/j.pharmthera.2012.12.007. View

18.

Tatsumi M, Groshan K, Blakely R, Richelson E . Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1998; 340(2-3):249-58. DOI: 10.1016/s0014-2999(97)01393-9. View

19.

Sriram K, Insel P . G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?. Mol Pharmacol. 2018; 93(4):251-258. PMC: 5820538. DOI: 10.1124/mol.117.111062. View

20.

Lymperopoulos A, Rengo G, Funakoshi H, Eckhart A, Koch W . Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med. 2007; 13(3):315-23. DOI: 10.1038/nm1553. View